• SenzaGen completed its acquisition of all shares in Alcyomics, a UK-based provider of non-animal immunotoxicology testing for drug development, today.
• The initial cash payment was approximately GBP 2.12 million (SEK 28 million).
• Conditional earn-out payments could total approximately GBP 1.88 million (SEK 25 million).
• Funding combined existing cash with a directed issue of SEK 25 million in convertible bonds to Eiffel Investment Group.
• Alcyomics generated approximately SEK 19.5 million in revenue in fiscal 2025/2026, with an EBITDA margin of approximately 24%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SenzaGen AB published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.